The Chemours Company

AI-generated fair value estimate for this company.

Method: 10-year two-stage unlevered FCF DCF: $300M normalized mid-cycle FCF base (TTM actual $218M, adjusted up modestly for lumpy litigation-related cash timing); 5% annual growth years 1-5; 3% years 6-10; 10% discount rate (elevated 4.4x net-leverage and PFAS litigation risk); 2% terminal growth; $3.24B net debt; 151M diluted shares.

Reasoning: Chemours is a highly leveraged, cyclical commodity-chemicals producer (TiO2, fluoroproducts) facing a material, partly-unresolved PFAS litigation overhang that dominates near-term GAAP results; a conservative FCF DCF with an elevated discount rate for leverage/legal risk, rather than relying on distorted GAAP net income, is the most defensible approach.